doi:10.3969/j.issn.1004-583X.2021.01.016

Abstract

CLC Number:

R593.22

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.01.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I1/75

References 44

[1]	Shaw M, Bridget FC, Lawrence AH, et al. Rheumatoid arthritis-associated lung disease[J]. Eur Respir Rev, 2015,24(135):1-16. doi: 10.1183/09059180.00008014 URL
[2]	Bendstrup E, Møller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians[J]. J Clin Med, 2019,8(12):2038. doi: 10.3390/jcm8122038 URL
[3]	Brusselle G. Rheumatoid arthritis and interstitial lung disease[J]. Rheumatology (Oxford), 2010,49(8):1425-1426. doi: 10.1093/rheumatology/keq017 pmid: 20223815
[4]	Ciancio N, Pavone M, Torrisi SE, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases[J]. Multidiscip Respir Med, 2019,14:17. doi: 10.1186/s40248-019-0179-2 URL
[5]	Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers[J]. Am J Respir Crit Care Med, 2015,191(12):1403-1412. doi: 10.1164/rccm.201411-1950OC URL
[6]	England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease[J]. Curr Opin Rheumatol, 2020,32(3):255-263. doi: 10.1097/BOR.0000000000000703 pmid: 32141954
[7]	熊琴, 杨彦瑜, 谭敏, 等. 原发性干燥综合征相关肺间质病变治疗的研究进展[J]. 临床荟萃, 2019,34(10):948-952.
[8]	Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease[J]. Rheumatol, 2013,40(5):640-646. doi: 10.1093/rheumatology/40.6.640 URL
[9]	Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects[J]. Am J Med Sci, 2009,337(5):329-335. doi: 10.1097/MAJ.0b013e31818d094b pmid: 19295413
[10]	Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease[J]. Respir Med, 2016,121:117-122. doi: 10.1016/j.rmed.2016.11.007 URL
[11]	吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识小组. 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识[J]. 中华风湿病学杂志, 2019,23(7):436-440.
[12]	Ota M, Iwasaki Y, Harada H, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease[J]. Mod Rheumatol, 2017,27(1):22-28. doi: 10.3109/14397595.2016.1173816 URL
[13]	王春雨, 罗晓红. 改善病情抗风湿药与类风湿关节炎肺间质病变[J]. 中华风湿病学杂志, 2018,22(6):426-429.
[14]	Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2014,7(3):492-509.
[15]	Tokano Y, Ogasawara H, Ando S, et al. Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease[J]. Mod Rheumatol, 2002,12(4):305-310. doi: 10.3109/s101650200054 pmid: 24383997
[16]	Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report[J]. J Korean Med Sci, 2002,17(2):270-273. pmid: 11961317
[17]	Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis[J]. Rheumatology (Oxford), 2000,39(12):1422-1424. doi: 10.1093/rheumatology/39.12.1422 URL
[18]	Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus[J]. Res, 2018,23(11):1041-1048.
[19]	谢文慧, 张卓莉. Janus酪氨酸激酶抑制剂治疗类风湿关节炎的现状与展望[J]. 中华风湿病学杂志, 2019,23(7):482-486.
[20]	Sho S, Jun S, Hirotaka Y, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice[J]. Arthritis Res Ther, 2019,21(1):184. doi: 10.1186/s13075-019-1963-2 URL
[21]	Cassone G, Manfredi A, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: Lights and shadows[J]. J Clin Med, 2020,9(4):1082. doi: 10.3390/jcm9041082 URL
[22]	Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.[J]. Immunopathol Pharmacol, 2014,27:1-10.
[23]	Vassallo R, Matteson E, Thomas CJ. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition[J]. Chest, 2002,122(3):1093-1096. pmid: 12226061
[24]	Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis[J]. Eur Respir J, 2004,24(4):708. pmid: 15459153
[25]	Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease[J]. Clin Exp Rheumatol, 2007,25(1):23-28. pmid: 17417986
[26]	Huang Y, Lin W, Chen Z, et al. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?[J]. Drug Des Devel Ther, 2019,13:2111-2125. doi: 10.2147/DDDT URL
[27]	Schultz R, Mattila J, Gappa M, et al. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic juvenile arthritis (CJA)[J]. Pediatr Pulmonol, 2001,32(5):397-402. doi: 10.1002/ppul.1149 URL
[28]	Wang Y, Xu SQ, Xu JH, et al. Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease[J]. Clin Med Insights Case Rep, 2011,4:49-52.
[29]	Lindsay K, Melsom R, Jacob BK, et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment[J]. Rheumatology (Oxford), 2006,45(8):1048-1049. doi: 10.1093/rheumatology/kel090 URL
[30]	姜少杰, 梁仕睿, 张雪芹, 等. IL-6/IL-6受体轴及其靶向抑制剂研究进展[J]. 细胞与分子免疫学杂志, 2019,35(6):569-574.
[31]	杜勤, 徐红娣. 托珠单抗对类风湿关节炎患者疗效、免疫球蛋白及辅助性T细胞水平的影响[J]. 药学实践杂志, 2020,38(1):71-73, 87.
[32]	Manfredi A, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study[J]. Intern Med J, 2019 Oct 29.[Online ahead of print]
[33]	英国警示托珠单抗的罕见严重肝损伤风险[J]. 中国药物评价, 2019,36(6):434.
[34]	Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease[J]. Respirology, 2014,19(3):353-359. doi: 10.1111/resp.2014.19.issue-3 URL
[35]	Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre[J]. Rheumatology (Oxford), 2017,56(8):1348-1357. doi: 10.1093/rheumatology/kex072 URL
[36]	MacIsaac J, Siddiqui R, Jamula E, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin[J]. Transfusion, 2018,58(11):2729-2735. doi: 10.1111/trf.14841 pmid: 30244480
[37]	Blair HA, Deeks ED. Abatacept: A review in rheumatoid arthritis[J]. Drugs, 2017,77(11):1221-1233. doi: 10.1007/s40265-017-0775-4 URL
[38]	Yamada H, Tsuru T, Otsuka T, et al. Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production[J]. Immunol Med, 2020 Jan 29; 1-5.[Online ahead of print]
[39]	Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G, et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis[J]. Exp Mol Pathol, 2011,91(3):718-722. doi: 10.1016/j.yexmp.2011.09.010 URL
[40]	Boleto G, Guignabert C, Pezet S, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis[J]. Arthritis Res Ther, 2018,20(1):197. doi: 10.1186/s13075-018-1694-9 URL
[41]	Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients[J]. Semin Arthritis Rheum, 2018,48(1):22-27. doi: 10.1016/j.semarthrit.2017.12.012 URL
[42]	Cassone G, Manfredi A, Atzeni F, et al. Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study[J]. J Clin Med, 2020,9(1):277. doi: 10.3390/jcm9010277 URL
[43]	Kurata I, Tsuboi H, Terasaki M, et al. Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis[J]. Intern Med, 2019,58(12):1703-1712. doi: 10.2169/internalmedicine.2226-18 URL
[44]	Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation[J]. Heart Lung Transplant, 2015,34(1):1-15. doi: 10.1016/j.healun.2014.06.014 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 44

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(8): 753-756.
[2]	. [J]. Clinical Focus, 2023, 38(7): 663-667.
[3]	. [J]. Clinical Focus, 2023, 38(3): 279-284.
[4]	Zhang Yueyue, Xie Meifang, Sun Gen. Rheumatoid arthritis complicated with T-cell large granular lymphocytic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(8): 728-732.
[5]	Hu Fangfang, Zhong Shiling, Di Yazhen, Wu Ling. Vascular endothelial function of juvenile idiopathic arthritis in pediatric patients: A systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(3): 204-210.
[6]	Lin Changyi, Song Minghui, Wu Peicheng. Difference between remitting seronegative symmetrical synovitis with pitting edema syndrome and seronegative rheumatoid arthritis [J]. Clinical Focus, 2022, 37(3): 262-265.
[7]	. [J]. Clinical Focus, 2022, 37(2): 188-192.
[8]	. [J]. Clinical Focus, 2022, 37(1): 92-96.
[9]	Liu Ziyi, Wang Jibo. Analysis of clinical characteristics and related factors of rheumatoid arthritis complicated with malignant tumors in patients [J]. Clinical Focus, 2021, 36(3): 246-250.
[10]	Chen Wenyu, Wang Juanjuan, Wang Zhiming. Clinical feature of pleural effusion in 78 patients with rheumatoid arthritis [J]. Clinical Focus, 2016, 31(2): 214-217.
[11]	Xie Qingyun, Wei Meng, Fu Peiliang, Sun Jiuyi, Qian Qirong. Association study between single nucleotide polymorphisms of interleukin 23 receptor and rheumatoid arthritis [J]. Clinical Focus, 2016, 31(1): 40-44.
[12]	Wang Lei;Zhang Guimin;Li Li;Yu Zhibo;Yan Yonglong;Zhang Fengxiao;Sun Lijun. Application of high frequency energy Doppler ultrasound in monitoring of rheumatoid arthritis treatment [J]. Clinical Focus, 2015, 30(12): 1405-1409.
[13]	. [J]. Clinical Focus, 2015, 30(12): 1429-1.43014e+007.
[14]	Luo Hong;Chen Yanfei. Expression of interleukin-1β in platelet of patients with rheumatoid arthritis [J]. Clinical Focus, 2015, 30(8): 903-905.
[15]	Xie Qingyun;Wei Meng;Wang Tao;Cheng Yue;Zhu Changliang. Lipid profile in active rheumatoid arthritis and disease activity correlation [J]. Clinical Focus, 2015, 30(8): 906-908914.